CN103242255A - 伊文氏蓝配合物及其制备方法和应用 - Google Patents
伊文氏蓝配合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN103242255A CN103242255A CN2013101571689A CN201310157168A CN103242255A CN 103242255 A CN103242255 A CN 103242255A CN 2013101571689 A CN2013101571689 A CN 2013101571689A CN 201310157168 A CN201310157168 A CN 201310157168A CN 103242255 A CN103242255 A CN 103242255A
- Authority
- CN
- China
- Prior art keywords
- compound
- solution
- azo
- preparation
- radiolabeled complexes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 title abstract 4
- 229960003699 evans blue Drugs 0.000 title abstract 4
- 238000010668 complexation reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 28
- 238000004108 freeze drying Methods 0.000 claims abstract description 13
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 claims abstract description 6
- 210000000056 organ Anatomy 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 76
- 239000000243 solution Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 238000011146 sterile filtration Methods 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 18
- 239000002953 phosphate buffered saline Substances 0.000 claims description 18
- 238000000746 purification Methods 0.000 claims description 17
- 238000000926 separation method Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- 239000008367 deionised water Substances 0.000 claims description 11
- 229910021641 deionized water Inorganic materials 0.000 claims description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 11
- 238000002372 labelling Methods 0.000 claims description 11
- 238000010025 steaming Methods 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 8
- 229940126214 compound 3 Drugs 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000002504 physiological saline solution Substances 0.000 claims description 7
- 238000013016 damping Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 230000009191 jumping Effects 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000011010 flushing procedure Methods 0.000 claims description 5
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 229940125782 compound 2 Drugs 0.000 claims description 3
- 229940125898 compound 5 Drugs 0.000 claims description 3
- ZFRBZRZEKIOGQI-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1,3-disulfonic acid Chemical compound C1=CC(O)=C2C(N)=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1 ZFRBZRZEKIOGQI-UHFFFAOYSA-N 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 238000010189 synthetic method Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 230000008569 process Effects 0.000 abstract description 4
- 239000003550 marker Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 abstract 1
- 230000009920 chelation Effects 0.000 abstract 1
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 abstract 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000012216 imaging agent Substances 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 240000002853 Nelumbo nucifera Species 0.000 description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 5
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310157168.9A CN103242255B (zh) | 2013-04-28 | 2013-04-28 | 伊文氏蓝配合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310157168.9A CN103242255B (zh) | 2013-04-28 | 2013-04-28 | 伊文氏蓝配合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103242255A true CN103242255A (zh) | 2013-08-14 |
CN103242255B CN103242255B (zh) | 2015-01-14 |
Family
ID=48922160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310157168.9A Active CN103242255B (zh) | 2013-04-28 | 2013-04-28 | 伊文氏蓝配合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103242255B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104650217A (zh) * | 2015-01-26 | 2015-05-27 | 汇佳生物科技(上海)有限公司 | 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用 |
WO2016209795A1 (en) | 2015-06-22 | 2016-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics |
WO2017196806A1 (en) | 2016-05-09 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
CN107629016A (zh) * | 2017-11-12 | 2018-01-26 | 莎穆(上海)生物科技有限公司 | 伊文氏蓝配合物及其制备方法和应用 |
WO2018051197A1 (en) * | 2016-09-19 | 2018-03-22 | The Hong Kong Polytechnic University | Chiral cyclen compounds and their uses |
CN109485642A (zh) * | 2018-11-21 | 2019-03-19 | 希施生物科技(上海)有限公司 | 一种制备伊文氏蓝衍生物的方法 |
WO2019070236A1 (en) | 2017-10-03 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIATION THERAPY AND IMAGING AGENTS |
CN114796532A (zh) * | 2022-04-20 | 2022-07-29 | 北京先通国际医药科技股份有限公司 | 放射性标记的伊文思蓝衍生物药物水溶液及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101109751A (zh) * | 2007-07-23 | 2008-01-23 | 山东省寄生虫病防治研究所 | 免疫荧光技术检测蚊虫体内登革病毒的方法 |
WO2009137471A2 (en) * | 2008-05-05 | 2009-11-12 | University Of Miami | Azo dye related small molecule modulators of protein-protein interactions |
WO2011146922A2 (en) * | 2010-05-21 | 2011-11-24 | Cytogel Pharma, Llc | Materials and methods for treatment of inflammation |
CN102488909A (zh) * | 2011-12-29 | 2012-06-13 | 江苏省中医药研究院 | 治疗性同位素标记的依文思蓝及其衍生物在制备肿瘤靶向放射治疗药物中应用 |
-
2013
- 2013-04-28 CN CN201310157168.9A patent/CN103242255B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101109751A (zh) * | 2007-07-23 | 2008-01-23 | 山东省寄生虫病防治研究所 | 免疫荧光技术检测蚊虫体内登革病毒的方法 |
WO2009137471A2 (en) * | 2008-05-05 | 2009-11-12 | University Of Miami | Azo dye related small molecule modulators of protein-protein interactions |
WO2011146922A2 (en) * | 2010-05-21 | 2011-11-24 | Cytogel Pharma, Llc | Materials and methods for treatment of inflammation |
CN102488909A (zh) * | 2011-12-29 | 2012-06-13 | 江苏省中医药研究院 | 治疗性同位素标记的依文思蓝及其衍生物在制备肿瘤靶向放射治疗药物中应用 |
Non-Patent Citations (1)
Title |
---|
LIXIN LANG,等: "Comparison Study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET Imaging of U87MG Tumors in Mice", 《BIOCONJUGATE CHEMISTRY》, 24 October 2011 (2011-10-24), pages 2415 - 2422 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104650217A (zh) * | 2015-01-26 | 2015-05-27 | 汇佳生物科技(上海)有限公司 | 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用 |
CN104650217B (zh) * | 2015-01-26 | 2018-08-10 | 莎穆(上海)生物科技有限公司 | 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用 |
WO2016209795A1 (en) | 2015-06-22 | 2016-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics |
US10709790B2 (en) | 2015-06-22 | 2020-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics |
US10696631B2 (en) * | 2016-05-09 | 2020-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
WO2017196806A1 (en) | 2016-05-09 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
CN109153641B (zh) * | 2016-05-09 | 2022-10-18 | 美国政府健康及人类服务部 | 伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途 |
CN109153641A (zh) * | 2016-05-09 | 2019-01-04 | 美国政府健康及人类服务部 | 伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途 |
WO2018051197A1 (en) * | 2016-09-19 | 2018-03-22 | The Hong Kong Polytechnic University | Chiral cyclen compounds and their uses |
CN109963839A (zh) * | 2016-09-19 | 2019-07-02 | 香港理工大学 | 手性轮环藤宁化合物及其用途 |
US11357873B2 (en) | 2016-09-19 | 2022-06-14 | The Hong Kong Polytechnic University | Chiral cyclen compounds and their uses |
WO2019070236A1 (en) | 2017-10-03 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIATION THERAPY AND IMAGING AGENTS |
US10981866B2 (en) | 2017-10-03 | 2021-04-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents |
CN107629016B (zh) * | 2017-11-12 | 2020-05-22 | 莎穆(上海)生物科技有限公司 | 伊文氏蓝配合物及其制备方法和应用 |
CN107629016A (zh) * | 2017-11-12 | 2018-01-26 | 莎穆(上海)生物科技有限公司 | 伊文氏蓝配合物及其制备方法和应用 |
CN109485642A (zh) * | 2018-11-21 | 2019-03-19 | 希施生物科技(上海)有限公司 | 一种制备伊文氏蓝衍生物的方法 |
CN114796532A (zh) * | 2022-04-20 | 2022-07-29 | 北京先通国际医药科技股份有限公司 | 放射性标记的伊文思蓝衍生物药物水溶液及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103242255B (zh) | 2015-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103242255B (zh) | 伊文氏蓝配合物及其制备方法和应用 | |
Volkert et al. | 99m Tc-propylene amine oxime (99m Tc-PnAO); a potential brain radiopharmaceutical | |
CN108434468B (zh) | 一种放射性碘标记的蛋白结合配体及其应用 | |
CN102014970B (zh) | 99mTc标记的含19个氨基酸的多肽作为磷脂酰乙醇胺结合分子探针和放射性药物的用途 | |
CN106543268B (zh) | 一种多功能影像探针及其制备方法和应用 | |
CN106084005A (zh) | 靶向生长抑素受体的Al18F‑NOTA‑PEG6‑TATE及其制备方法和应用 | |
CN112043838B (zh) | 一种ace2受体靶向核素多肽探针及其制备方法和应用 | |
CN109414514A (zh) | Pet成像免疫调节剂 | |
Hausner et al. | In vitro and in vivo evaluation of the effects of aluminum [18F] fluoride radiolabeling on an integrin αvβ6-specific peptide | |
CN103041412B (zh) | 一种具有fshr靶向性的pet示踪剂及其制备方法与应用 | |
CN103153350A (zh) | 肽放射性示踪剂组合物 | |
Summer et al. | Developing targeted hybrid imaging probes by chelator scaffolding | |
CN104725473A (zh) | 一种[18F]AlF标记的PET多肽探针及其制备方法 | |
CN107847618A (zh) | Hbed‑二膦酸盐/酯、其放射金属轭合物和它们作为治疗诊断剂的用途 | |
US9789211B2 (en) | Methods and compositions for positron emission tomography myocardial perfusion imaging | |
CN111675750B (zh) | 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用 | |
CN107308466A (zh) | 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用 | |
CN107629016B (zh) | 伊文氏蓝配合物及其制备方法和应用 | |
CN108434469A (zh) | 一种HER2亲合体的68Ga标记物及其制备方法、应用 | |
CN109824760A (zh) | 奥曲肽类生长抑素前体化合物、配体化合物及制备和应用 | |
US20150374861A1 (en) | Kit for tumor imaging | |
CN109705193B (zh) | 一种放射性标记tEB-TMTP1化合物及其制备方法和应用 | |
CN105884867B (zh) | 18f标记的亲合体类化合物及其制备方法与应用 | |
US10561379B2 (en) | In vivo positron emission tomography-based perfusion/blood pool imaging using labeled erythrocytes | |
CN115286693A (zh) | 针对癌胚抗原相关细胞黏附分子ceacam6的肿瘤靶向肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220113 Address after: 361000 Building 2, Xiamen University, Siming District, Xiamen City, Fujian Province Patentee after: Xiamen University Asset Management Co.,Ltd. Patentee after: Zhang Xianzhong Address before: 361000 Siming South Road, Xiamen, Fujian Province, No. 422 Patentee before: XIAMEN University Effective date of registration: 20220113 Address after: 361000 unit 505-3, No. 23, Jiahe Road, Siming District, Xiamen City, Fujian Province Patentee after: Xiamen ruipusi Technology Co.,Ltd. Address before: 361000 Building 2, Xiamen University, Siming District, Xiamen City, Fujian Province Patentee before: Xiamen University Asset Management Co.,Ltd. Patentee before: Zhang Xianzhong |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240117 Address after: Room 101, Building 52, No. 500, Binhai East Road, Muping District, Yantai City, Shandong Province, 264199 Patentee after: Yantai Lannacheng Biotechnology Co.,Ltd. Address before: 361000 unit 505-3, No. 23, Jiahe Road, Siming District, Xiamen City, Fujian Province Patentee before: Xiamen ruipusi Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |